Related Experiment Video
Updated: Jun 6, 2025
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
TMEM35B as a novel biomarker for diagnosing gliomas
Gongbo Liang1, Xuwen Lai1, Guangning Yan1
1Department of Pathology, General Hospital of Southern Theater Command, Guangzhou, R.P. China.
Aims:
There is little information about transmembrane protein 35B (TMEM35B) expression in glioma, and its functions in glioma remains no clue.
Patients & Methods:
Immunohistochemistry was used to measure TMEM35B expression levels and CCK8 and Transwell assays were analyzed the proliferative and migratory and invasive.
Results:
TMEM35B protein was significantly higher in gliomas and correlated with a higher tumor TNM stages. Receiver operating characteristic curve analysis revealed that TMEM35B had high diagnostic value in distinguishing among glioma, normal tissues, tumor stages III+IV, and I+II. Additionally, TMEM35B knockdown inhibited the proliferative, migratory, and invasive capacities of glioma cells.
Conclusions:
TMEM35B expression is upregulated in gliomas, and its knockdown hinders tumor progression, highlighting the protein as a potential biomarker for glioma diagnosis.
Insights
Transmembrane protein 35B (TMEM35B) is elevated in gliomas and promotes tumor growth. TMEM35B shows potential as a diagnostic biomarker for glioma, as reducing its levels inhibits cancer cell progression.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Limited information exists on transmembrane protein 35B (TMEM35B) expression and function in glioma.
- Understanding TMEM35B's role is crucial for advancing glioma research.
Purpose of the Study:
- To investigate TMEM35B expression levels in glioma.
- To determine the functional role of TMEM35B in glioma cell proliferation, migration, and invasion.
- To evaluate TMEM35B as a potential diagnostic biomarker for glioma.
Main Methods:
- Immunohistochemistry was employed to quantify TMEM35B expression in glioma tissues.
- Cell proliferation, migration, and invasion were assessed using CCK8 and Transwell assays.
- Receiver operating characteristic (ROC) curve analysis was performed to evaluate diagnostic value.
Main Results:
- TMEM35B protein levels were significantly higher in gliomas compared to normal tissues.
- Elevated TMEM35B expression correlated with advanced tumor TNM stages (III+IV vs. I+II).
- TMEM35B knockdown significantly inhibited glioma cell proliferation, migration, and invasion.
Conclusions:
- TMEM35B is upregulated in gliomas and contributes to tumor progression.
- TMEM35B knockdown demonstrates anti-tumor effects on glioma cells.
- TMEM35B serves as a promising diagnostic biomarker for glioma.
